bullish
Pharmaron (康龙化成) A+H: Decent H/A Discount and Cornerstone Line-Up
568 Views12 Nov 2019 15:25
Pharmaron, the secondly largest CRO based in China, launched book building today to raise up to USD 588 million to list in Hong Kong. In our...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 2-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Long Pharmaron/Short Wuxi: Take Profit Now, A-Share Pullback the Key Risk23 Jan 2020
- Pharmaron (康龙化成) Post-IPO: A/H Convergence Post Connect Inclusion Supports A Trade02 Jan 2020
- Pharmaron (康龙化成) A+H: Allocation and Thoughts on Trading27 Nov 2019
- Pharmaron (康龙化成) A+H Listing: 3Q2019 Numbers and Thoughts on Valuation06 Nov 2019
- Pharmaron (康龙化成) A+H Listing: A Leading Drug Discovery Company28 Aug 2019
x